Chronic obstructive pulmonary disease: clinucal issues, epidemiology, risk factors and the basic therapy (review)

Cover Page

Cite item

Full Text

Abstract

Chronic obstructive pulmonary disease (COPD) is a serious medical problem. Based on the research Global Alliance Against Chronic Respiratory Diseases (GARD), the prevalence of COPD in the population to 15.3%. Installed external and internal risk factors of COPD. For patients, COPD is a significant impact of the disease on their daily activities and is often accompanied by one or more concomitant diseases and/or systemic effects. Elevated inflammatory markers significantly associated with increased all-cause mortality among COPD patients, and increased physical activity reduces systemic inflammation. It is noted that the value of dietary fiber may also be related to their anti-inflammatory and antioxidant effects. The article emphasizes that the clinical phenotypes of COPD can be a composite, because they can change under the influence of therapy and/or as a result of the usual course of the disease. At the expressed symptoms of COPD starting treatment should be their long-acting beta-2-agonists and M-holinolytics. The issue of supplemental inhaled corticosteroids and phosphodiesterase-4 inhibitors is solved according to the features of the further course of COPD.

About the authors

I. V Leshchenko

Ural State Medical University of the Ministry of Health of the Russian Federation; Medical Association «Novaya Bolnitza»

Email: leshhcenkoiv@mail.ru
д-р мед. наук, проф. каф. фтизиатрии и пульмонологии ФГБОУ ВО УГМУ, науч. рук. клиники ООО МО «Новая больница» 620028, Russian Federation, Yekaterinburg, ul. Repina, d. 3; 620109, Russian Federation, Yekaterinburg, ul. Zavodskaia, d. 29

I. I Baranova

Ural State Medical University of the Ministry of Health of the Russian Federation; Medical Association «Novaya Bolnitza»

Email: baranovailona@gmail.com
канд. мед. наук, ассистент каф. фтизиатрии и пульмонологии ФГБОУ ВО УГМУ, врач-пульмонолог пульмонологической клиники ООО МО «Новая больница» 620028, Russian Federation, Yekaterinburg, ul. Repina, d. 3; 620109, Russian Federation, Yekaterinburg, ul. Zavodskaia, d. 29

References

  1. Lozano R, Naghavi M, Foreman K et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematiс analysis for the Global Burden of Disease Study 2010. Lancet 2012; 380: 2095-128.
  2. Minino A.M, Xu J, Kochanek K.D. Deaths: preliminary data for 2008. Natl Vital Stat Rep 2010; 59: 1-52.
  3. Anto J.M, Vermeire P, Vestbo J, Sunyer J. Epidemiology of chronic obstructive pulmonary disease. ERS J Ltd 2001.
  4. Thun M.J, Carter B.D, Feskanich D et al. 50-year trends in smoking - related mortality in the United States. N Engl J Med 2013; 368: 351-64.
  5. Guarascio A.J, Ray S.M, Finch C.K et al. The clinical and economic burden of chronic obstructive pulmonary disease in the USA. Clinicoecon Outcomes Res 2013; 5: 235-45.
  6. Chuchalin A.G, Khaltaev N, Antonov N.S et al. Chronic respiratory diseases and risk factors in 12 regions of the Russian Federation. Int J COPD 2014; 12: 963-74.
  7. Aisanov Z, Bai C, Bauerle O et al. Primary care physician perceptions on the diagnosis and management of chronic obstructive pulmonary disease in diverse regions of the world. Int J COPD 2012; 7: 1-12.
  8. Lamprecht B, Soriano J.B, Studnicka M et al. BOLD Collaborative Research Group, the EPI-SCAN Team, the PLATINO Team, and the PREPOCOL Study Group. Determinants of underdiagnosis of COPD in national and international surveys. Chest 2015; 148 (4): 971-85.
  9. Menezes A.M, Perez-Padilla R, Hallal P.C et al. Worldwide burden of COPD in high - and low - income countries. Part II. Burden of chronic obstructive lung disease in Latin America: the PLATINO study Int J Tuberc Lung Dis 2008; 12: 709-12.
  10. Global Strategy for the Diagnosis, Management, and Prevention of COPD. Updated 2016. www.goldcopd.com
  11. Vermeire P, Vestbo J, Viegi G et al. Recommendations for epidemiological studies on COPD. Eur Respir J 2011; 38: 1261-77.
  12. Федеральные клинические рекомендации по диагностике и лечению хронической обструктивной болезни легких. Пульмонология. 2014; 3: 15-61.
  13. Vestbo J, Hurd S.S, Agusti A.G et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2013; 187: 347-65.
  14. Hardie J.A, Buist A.S, Vollmer W.M et al. Risk of over - diagnosis of COPD in asymptomatic elderly never - smokers. Eur Respir J 2002; 20: 1117-22.
  15. Cerveri I, Corsico A.G, Accordini S et al. Underestimation of airflow obstruction among young adults using FEV1/FVC<70% as a fixed cut - off: a longitudinal evaluation of clinical and functional outcomes. Thorax 2008; 63: 1040-5.
  16. Celli B.R, Decramer M et al. An official American Thoracic Society/European Respiratory Society statement: research questions in COPD. Eur Respir J 2015; 45: 879-905.
  17. Jones P, Lareau S, Mahler D.A. Measuring the effects of COPD on the patient. Respir Med 2005; 99 (Suppl. 2): S11-S18.
  18. Arnold R, Ranchor A.V, Koeter G.H et al. Consequences of chronic obstructive pulmonary disease and chronic heart failure: the relationship between objective and subjective health. Soc Sci Med 2005; 61: 2144-54.
  19. Ware J.E Jr, Gandek B. Overview of the SF-36 Health Survey and the International Quality of Life Assessment (IQoLA) project. J Clin Epidemiol 1998; 51: 903-12.
  20. Schunemann H.J, Goldstein R, Mador M.J et al. A randomised trial to evaluate the self - administered standardized chronic respiratory questionnaire. Eur Respir J 2005; 25: 31-40.
  21. Maille A.R, Koning C.J, Zwinderman A.H et al. The development of the "Quality - of - life for Respiratory Illness Questionnaire (QoL-RIQ)'': a disease - specific quality - of - life questionnaire for patients with mild to moderate chronic nonspecific lung disease. Respir Med 1997; 91: 297-309.
  22. Hajiro T, Nishimura K, Tsukino M et al. Analysis of clinical methods used to evaluate dyspnea in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998; 158: 1185-9.
  23. Mahler D.A. Measurement of dyspnea: clinical ratings. In: Mahler D.A, ed. Dyspnea: Mechanisms, measurement and management. 2nd ed. New York: Taylor & Francis Inc., 2005; p. 147-64.
  24. Borg G.A. Psychophysical bases of perceived exertion. Med Sci Sports Exerc 1982; 14: 377-81.
  25. Rostron B.L, Chang C.M, Pechacek T.F. Estimation of cigarette smoking - attributable morbidity in the United States. JAMA Intern Med 2014; 174: 1922-8.
  26. Salvi S.S, Barnes P.J. Chronic obstructive pulmonary disease in non - smokers. Lancet 2009; 374: 733-43.
  27. Anto J.M, Vermeire P, Vestbo J, Sunyer J. Epidemiology of chronic obstructive pulmonary disease. Eur Respir J 2001; 17: 982-94.
  28. Lokke A, Lange P, Scharling H et al. Developing COPD: a 25 year follow up study of the general population. Thorax 2006; 61: 935-9.
  29. Pillai S.G, Ge D, Zhu G et al. A genome - wide association study in chronic obstructive pulmonary disease (COPD): identification of two major susceptibility loci. PLoS Genet 2009; 5: e1000421.
  30. Kim W.J, Lee S.D. Candidate genes for COPD: current evidence and research. Int J COPD 2015; 10: 2249-55.
  31. Zhao Z, Peng F, Zhou Y et al. Exon sequencing identifies a novel CHRNA3-CHRNA5CHRNB4 variant that increases the risk for chronic obstructive pulmonary disease. Respirology 2015; 20: 790-8.
  32. Horita N, Miyazawa N, Tomaru K et al. Vitamin D binding protein genotype variants and risk of chronic obstructive pulmonary disease: a meta - analysis. Respirology 2015; 20: 219-25.
  33. Ou C-Y, Chen C-Z, Hsiue T-R et al. Genetic variants of pulmonary SP-D predict disease outcome of COPD in a Chinese population. Respirology 2015; 20: 296-303.
  34. Chubachi S, Nakamura H, Sasaki M et al. Polymorphism of LRP5 gene and emphysema severity are associated with osteoporosis in Japanese patients with or at risk for COPD. Respirology 2015; 20: 286-95.
  35. Negewo N.A, Gibson P.G, Mc Donald V.M. COPD and its comorbidities: impact, measurement and mechanisms. Respirology 2015; 20: 1160-71.
  36. Drazen J.M, Fabbri L.M. Ageing and multimorbidity. Eur Respir J 2014; 44: 557.
  37. Faner R, Cruz T, Lopez-Giraldo A et al. Network medicine, multimorbidity and the lung in the elderly. Eur Respir J 2014; 44: 775-88.
  38. Divo M.J, Martinez C.H, Mannino D.M. Ageing and the epidemiology of multimorbidity. Eur Respir J 2014; 44: 1055-68.
  39. Patel A.R, Donaldson G.C, Mackay A.J et al. The impact of ischemic heart disease on symptoms, health status, and exacerbations in patients with COPD. Chest 2012; 141: 851-7.
  40. Mannino D.M, Thorn D, Swensen A et al. Prevalence and outcomes of diabetes, hypertension and cardiovascular disease in COPD. Eur Respir J 2008; 32: 962-9.
  41. Wilson D.O, Leader J.K, Fuhrman C.R et al. Quantitative computed tomography analysis, airflow obstruction, and lung cancer in the Pittsburgh lung screening study. J Thorac Oncol 2011; 6: 1200-5.
  42. Calverley P.M, Anderson J.A, Celli B et al. TORCH investigators. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007; 356: 775-89.
  43. Vanfleteren L.E, Spruit M.A, Groenen M et al. Clusters of comorbidities based on validated objective measurements and systemic inflammation in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2013; 187: 728-35.
  44. Roca M, Verduri A, Corbetta L et al. Mechanisms of acute exacerbation of respiratory symptoms in chronic obstructive pulmonary disease. Eur J Clin Invest 2013; 43: 510-21.
  45. Donaldson G.C, Hurst J.R, Smith C.J et al. Increased risk of myocardial infarction and stroke following exacerbation of COPD. Chest 2010; 137: 1091-7.
  46. Bowler R.P, Kim V, Regan E et al. COPD Gene Investigators. Prediction of acute respiratory disease in current and former smokers with and without COPD. Chest 2014; 146: 941-50.
  47. Tan W.C, Bourbeau J, Hernandez P et al. Can COLD Collaborative Research Group. Exacerbation - like respiratory symptoms in individuals without chronic obstructive pulmonary disease: results from a population - based study. Thorax 2014; 69: 709-17.
  48. Marin J.M, Soriano J.B, Carrizo S.J et al. Outcomes in patients with chronic obstructive pulmonary disease and obstructive sleep apnea: the overlap syndrome. Am J Respir Crit Care Med 2010; 182: 325-31.
  49. Ingebrigtsen T.S, Marott J.L, Vestbo J et al. Gastro - esophageal reflux disease and exacerbations in chronic obstructive pulmonary disease. Respirology 2015; 20: 101-7.
  50. Jung J.Y, Kim Y.S, Kim S.K et al. KOLD Study. Relationship of vitamin D status with lung function and exercise capacity in COPD. Respirology 2015; 20: 782-9.
  51. Lange N.E, Sparrow D, Vokonas P, Litonjua A.A. Vitamin D deficiency, smoking, and lung function in the Normative Aging Study. Am J Respir Crit Care Med 2012; 186 (7): 616-21.
  52. Kunisaki K.M, Niewoehner D.E, Singh R.J, Connett J.E. Vitamin D status and longitudinal lung function decline in the Lung Health Study. Eur Respir J 2011; 37 (2): 238-43.
  53. Britton J.R, Pavord I.D, Richards K.A et al. Dietary antioxidant vitamin intake and lung function in the general population. Am J Respir Crit Care Med 1995; 151: 1383-7.
  54. Ford E.S, Cunningham T.J, Mannino D.M. Inflammatory markers and mortality among US adults with obstructive lung function. Respirology 2015; 20: 587-93.
  55. Eltboli O, Mistry V, Barker B. Relationship between blood and bronchial submucosal eosinophilia and reticular basement membrane thickening in chronic obstructive pulmonary disease. Respirology 2015; 20: 667-70.
  56. Ijiri N, Kanazawa H, Asai K et al. Irisin, a newly discovered myokine, is a novel biomarker associate with physical activity in patients with chronic obstructive pulmonary disease. Respirology 2015; 20: 612-7.
  57. Ferrer M, Alonso J, Morera J et al. Chronic obstructive pulmonary disease stage and health - related quality of life. The Quality of Life of Chronic Obstructive Pulmonary Disease Study Group. Ann Intern Med 1997; 127: 1072-9.
  58. Ofir D, Laveneziana P, Webb K.A et al. Mechanisms of dyspnea during cycle exercise in symptomatic patients with GOLD stage I chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2008; 177: 622-9.
  59. Chin R.C, Guenette J.A, Cheng S et al. Does the respiratory system limit exercise in mild chronic obstructive pulmonary disease? Am J Respir Crit Care Med 2013; 187: 1315-23.
  60. Mac Nee W. Oxidants/antioxidants and COPD. Chest 2000; 117: 303-17S.
  61. Brown C.A, Crombie I.K, Tunstall-Pedoe H. Failure of cigarette smoking to explain international differences in mortality from chronic obstructive pulmonary disease. J Epidemiol Community Health 1994; 48: 134-9.
  62. Caballero A, Torres-Duque C.A, Jaramillo C et al. Prevalence of COPD in five Colombian cities situated at low, medium, and high altitude (PREPOCOL study). Chest 2008; 133 (2): 343-9.
  63. Kanervisto M, Vasankari T, Laitinen T et al. Low socioeconomic status is associated with chronic obstructive airway diseases. Respir Med 2011; 105 (8): 1140-6.
  64. Harik-Khan R.I, Fleg J.L, Wise R.A. Body mass index and the risk of COPD. Chest 2002; 121 (2): 370-6.
  65. Lamprecht B, Schirnhofer L, Kaiser B et al. Non - reversible airway obstruction in never smokers: results from the Austrian BOLD study. Respir Med 2008; 102 (12): 1833-8.
  66. Buist A.S, Mc Burnie M.A, Vollmer W.M et al. International variation in the prevalence of COPD (the BOLD Study): a population - based prevalence study. Lancet 2007; 370 (9589): 741-50.
  67. Eisner M.D. Indoor air, passive smoking, and COPD. Am J Respir Crit Care Med 2007; 176 (5): 426-7.
  68. Salvi S.S, Barnes P.J. Chronic obstructive pulmonary disease in non - smokers. Lancet 2009; 374 (9691): 733-43; Nizankowska-Mogilnicka E, Mejza F, Buist A.S et al. Prevalence of COPD and tobacco smoking in Malopolska region - results from the BOLD study in Poland. Pol Arch Med Wewn 2007; 117 (9): 402-10.
  69. Pasipanodya J.G, Miller T.L, Vecino M et al. Pulmonary impairment after tuberculosis. Chest 2007; 131 (6): 1817-24.
  70. Hnizdo E, Singh T, Churchyard G. Chronic pulmonary function impairment caused by initial and recurrent pulmonary tuberculosis following treatment. Thorax 2000; 55 (1): 32-8.
  71. Lee Y.K, Nam H.S, Chuang L.H et al. South Korean time trade - off values for EQ-5D health states: modeling with observed values for 101 health states. Value Health 2009; 12 (8): 1187-93.
  72. Elkington P.T, Friedland J.S. Matrix metalloproteinases in destructive pulmonary pathology. Thorax 2006; 61 (3): 259-66.
  73. Kim S.H, Oh Y.M, Jo M.W. Health - related quality of life in chronic obstructive pulmonary disease patients in Korea. Health Qual Life Outcomes 2014; 12: 57.
  74. Freimer N, Sabatti C. The human phenome project. Nat Genet 2003; 34: 15-21.
  75. Han M.K, Agusti A, Calverley P.M et al. Chronic obstructive pulmonary disease phenotypes: the future of COPD. Am J Respir Crit Care Med 2010; 182: 598-604.
  76. Vestbo J, Hurd S.S, Agusti A.G et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2013; 187: 347-65.
  77. Barker B.L, Brightling C.E. Phenotyping the heterogeneity of chronic obstructive pulmonary disease Clinical Science 2013; 124: 371-87 (Printed in Great Britain). doi: 10.1042/CS20120340.
  78. Schols A.M, Ferreira I.M, Franssen F.M et al. Nutritional assessment and therapy in COPD: a European Respiratory Society statement.
  79. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO workshop report. Last updated 2016. www.goldcopd.org/
  80. Cheyne L, Irvin-Sellers M.J, White J. Tiotropium versus ipratropium bromide for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2015; 22 (9). CD009552.
  81. Karner C, Chong J, Poole P. Tiotropium versus placebo for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2014; 7. CD009285. doi: 10.1002/14651858.CD009285.pub3.
  82. Ulrik C. Once - daily glycopyrronium bromide (Seebri BreezhalerR) for the treatment of chronic obstructive pulmonary disease (COPD). Expert Opin Pharmacother 2015; 16 (17): 2653-9. doi: 10.1517/14656566.2015.1100171.
  83. Riario-Sforza G.G, Ridolo E et al. Glycopyrronium bromide for the treatment of chronic obstructive pulmonary disease. Expert Rev Respir Med 2015; 9 (1): 23-33. doi: 10.1586/17476348.2015.996133.
  84. Ni H, Soe Z, Moe S. Aclidinium bromide for stable chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2014; 19 (9). CD010509. DOI: 10.1002/ 14651858. CD010509.pub2.
  85. Zou Y, Xiao J, Yang D.H et al. Efficacy and Safety of an Aclidinium Bromide Treatment for 12 Weeks or Longer in Patients with Moderate - To - Severe COPD: A Meta - Analysis. COPD 2016; 13 (4): 499-508.
  86. Karabis A, Lindner L, Mocarski M et al. Comparative efficacy of aclidinium versus glycopyrronium and tiotropium, as maintenance treatment of moderate to severe COPD patients: a systematic review and network meta - analysis. Int J Chron Obstruct Pulmon Dis 2013; 8: 405-23. doi: 10.2147/COPD.S48967.
  87. Greake J.B. Indacaterol, a once - daily beta2 - agonist, versus twice - daily beta2 - agonists or placebo for COPD. Cochrane Database Syst Rev 2015; 10 (1). CD010139.
  88. Dhillon S. Tiotropium/Olodaterol: A Review in COPD. Drugs 2016; 76 (1): 135-46. doi: 10.1007/s40265-015-0527-2.
  89. Ramadan W.H, Kabbara W.K, El Khoury G.M, Al Assir S.A. Combined bronchodilators (tiotropium plus olodaterol) for patients with chronic obstructive pulmonary disease. Int J Chron. Obstruct Pulmon Dis 2015; 30 (10): 2347-56. doi: 10.2147/COPD.S88246. eCollection 2015. Review.
  90. Rodrigo G.J, Plaza V. Efficacy and safety of a fixed - dose combination of indacaterol and Glycopyrronium for the treatment of COPD: a systematic review 2014; 146 (2): 309-17. doi: 10.1378/chest.13-2807.
  91. Frampton J.E. QVA149 (indacaterol/glycopyrronium fixed - dose combination): a review of its use in patients with chronic obstructive pulmonary disease. Drugs 2014; 74 (4): 465-88. doi: 10.1007/s40265-014-0194-8.
  92. Watz H, Mailänder C, Baier M, Kirsten A. Effects of indacaterol/glycopyrronium (QVA149) on lung hyperinflation and physical activity in patients with moderate to severe COPD: a randomised, placebo - controlled, crossover study (The MOVE Study). BMC Pulm Med 2016; 16 (1): 95. doi: 10.1186/s12890-016-0256-7.
  93. Wedzicha J.A, Benerji D, Chapman K.R et al. Indacaterol - Glycopyrronium versus Salmeterol - Fluticasone for COPD. N Engl J Med 2016; 374 (23): 2222-34.
  94. Spyratos D, Sichletidis L. Umeclidinium bromide/vilanterol combination in the treatment of chronic obstructive pulmonary disease: a review. Ther Clin Risk Manag 2015; 11: 481-7. doi: 10.2147/TCRM.S67491. eCollection 2015. Review.
  95. Rodrigo G.J, Neffen H.A. Systematic Review of the Efficacy and Safety of a Fixed - Dose Combination of Umeclidinium and Vilanterol for the Treatment of COPD. Chest 2015; 148 (2): 397-407. doi: 10.1378/chest.15-0084. Review.
  96. Matera M.G, Sanduzzi A, Cazzola M. Specific role of combination aclidinium: formoterol in the treatment of chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis 2016; 11: 73-9. doi: 10.2147/COPD.S78000. eCollection 2016. Review.
  97. Mc Keage K. Fluticasonefuroate/vilanterol: a review of its use in chronic obstructive pulmonary disease. Drugs 2014; 74 (13): 1509-22. doi: 10.1007/s40265-014-0269-6. Review.
  98. Singh D, Corradi M, Spinola M et al. Extra fine beclometasone diproprionate/formoterol fumarate: a review of its effects in chronic obstructive pulmonary disease. NPJ Prim Care Respir Med 2016; 16 (26): 16030. doi: 10.1038/npjpcrm.2016.30. Review.
  99. Rojas-Reyes M, Morales O.M.G, Dennis R.J, Karner C. Combination inhaled steroid and long - acting beta2-agonist in addition to tiotropium versus tiotropium or combination alone for chronic obstructive pulmonary diseasee. Cochrane Database Syst Rev 2016; 6 (6). CD008532.
  100. Frith P.A, Thompson P.J, Ratnavadivel R et al. Glisten Study Group Glycopyrronium once - daily significantly improves lung function and health status when combined with salmeterol/fluticasone in patients with COPD: the GLISTEN study, a randomised controlled trial. Thorax 2015; 70 (6): 519-27. doi: 10.1136/thoraxjnl-2014-206670.
  101. Chong J, Leung B, Poole P. Phosphodiesterase 4 inhibitors for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews, 2013. Issue 11. Art. No.: CD002309. doi: 10.1002/14651858.CD002309.pub4.
  102. Martinez F.J, Calverley P.M.A, Goehring U-M et al. Effect of roflumilast on exacerbations in patients with severe chronic obstructive pulmonary disease uncontrolled by combination therapy (REACT): a multicentre randomized controlled trial. Lancet 2015; 385: 857-66.
  103. Zheng J.P, Wen F.Q, Bai C.X et al. Twice daily N-acetylcysteine 600 mg for exacerbations of chronic obstructive pulmonary disease (PANTHEON): a randomised, double - blind placebo - controlled trial. Lancet Respir Med 2014; 2 (3): 187-94.
  104. Cazzola M, Calzetta L, Clive Page C et al. Influence of N-acetylcysteine on chronic bronchitis or COPD exacerbations: a meta - analysis. Eur Respir Rev 2015; 24: 451-61.
  105. Pascoe S, Locantore N, Dransfield M.T et al. Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomised controlled trials. Lancet Respir Med 2015; 3 (6): 435-42.
  106. Siddiqui S.H, Guasconi A, Vestbo J et al. Blood Eosinophils: A Biomarker of Response to Extrafine Beclomethasone/Formoterol in Chronic Obstructive Pulmonary Disease. Am J Resp Crit Care Med 2015; 192 (4): 523-5.
  107. Barnes N.C, Sharma R, Lettis S et al. Blood eosinophils as a marker of response to inhaled corticosteroids in COPD. Eur Resp J 2016; 47 (5): 1374-82.
  108. Watz H, Tetziaff K, Wouters F.M et al. Blood eosinophil count and exacerbations in severe chronic obstructive pulmonary disease after withdrawal of inhaled corticosteroids: a post - hoc analysis of the WISDOM trial. Lancet Resp Med 2016; 4 (5): 390-8.
  109. Miravitlles M, D’Urzo A, Singh D.D, Koblizek V. Pharmacological strategies to reduce exacerbation risk in COPD: a narrative review. Respir Res 2016; 17: 112. doi: 10.1186/s12931-016-0425-5.
  110. Лещенко И.В., Авдеев С.Н. Хроническая обструктивная болезнь легких: индикаторы качества, алгоритм диагностики и терапии. РМЖ. 2016; 16: 1039-46

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2016 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Согласие на обработку персональных данных

 

Используя сайт https://journals.rcsi.science, я (далее – «Пользователь» или «Субъект персональных данных») даю согласие на обработку персональных данных на этом сайте (текст Согласия) и на обработку персональных данных с помощью сервиса «Яндекс.Метрика» (текст Согласия).